Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:clinical_trial
|
| gptkbp:alsoKnownAs |
Mosaico trial
|
| gptkbp:clinicalTrials.govID |
NCT03964415
|
| gptkbp:collaboratesWith |
gptkb:National_Institute_of_Allergy_and_Infectious_Diseases
gptkb:HIV_Vaccine_Trials_Network |
| gptkbp:endDate |
2022
lack of efficacy |
| https://www.w3.org/2000/01/rdf-schema#label |
HVTN 706
|
| gptkbp:intervention |
Ad26.Mos4.HIV vaccine
Mosaic-based HIV vaccine |
| gptkbp:location |
gptkb:Argentina
gptkb:Brazil gptkb:Italy gptkb:Mexico gptkb:Peru gptkb:Poland gptkb:Spain gptkb:United_States |
| gptkbp:participants |
3900
|
| gptkbp:period |
Phase 3
|
| gptkbp:sponsor |
Janssen Vaccines
|
| gptkbp:startDate |
2019
|
| gptkbp:status |
terminated
|
| gptkbp:studiedBy |
HIV vaccine
|
| gptkbp:targetAudience |
transgender individuals
cisgender men |
| gptkbp:bfsParent |
gptkb:HIV_Vaccine_Trials_Network
|
| gptkbp:bfsLayer |
7
|